The NSAIDs market encompasses medications like ibuprofen, naproxen, and diclofenac, widely used to alleviate pain, reduce inflammation, and lower fever. These drugs are available in various formats—oral pills, topical gels, and parenteral formulations—and can be purchased through hospital pharmacies, retail outlets, and online stores. The market is driven by rising incidence of chronic inflammatory conditions (such as arthritis and migraines), strong consumer preference for over-the-counter remedies over opioids, and advancements in safer formulations (like COX‑2 inhibitors and topical applications). Despite concerns over side effects such as gastrointestinal irritation and cardiovascular risks, demand continues to grow thanks to expanded distribution, improved treatment options, and increased healthcare access globally.
According to Fortune Business Insights, the global non-steroidal anti-inflammatory drugs (NSAIDs) market was valued at USD 15.58 billion in 2019 and is projected to reach USD 32.33 billion by 2032, exhibiting a CAGR of 5.8% during the forecast period. In 2019, North America dominated the NSAIDs market with a market share of 44.03%.
In May 2019, Perrigo Company secured FDA approval for an Abbreviated New Drug Application (ANDA) referencing Voltaren Gel, marking a milestone in topical NSAID accessibility .
Chronic Pain Prevalence: Widespread conditions like arthritis, migraine, and ophthalmic disorders (e.g., post-surgery inflammation) push NSAIDs into the forefront. CDC data reveals over 50 million U.S. adults experience chronic pain, with 19.6 million suffering high-impact pain .
NSAIDs over Opioids: Growing recognition of opioid risks since late 2010s encourages safer, non-addictive NSAID use. Ibuprofen and naproxen are now primary line therapies per family physician guidelines .